Genentech Avastin Clears FDA; Colorectal Cancer Drug Costs $4,400 A Month
Executive Summary
Genentech is launching its oncologic Avastin at a wholesale acquisition cost of $2,200 per dose for the average colorectal cancer patient
You may also be interested in...
Targeted Oncologics Will Sustain High Prices With Clear Benefits, GSK Says
The high price tags of targeted therapies will continue to be supported as specific populations are identified where the oncologics can show a clear benefit, according to GlaxoSmithKline Chairman of R&D Tachi Yamada
Targeted Oncologics Will Sustain High Prices With Clear Benefits, GSK Says
The high price tags of targeted therapies will continue to be supported as specific populations are identified where the oncologics can show a clear benefit, according to GlaxoSmithKline Chairman of R&D Tachi Yamada
Avastin Pricing Strategy, Expanded Indications Under Review At Genentech
Genentech may reconsider pricing forAvastin following "phenomenal" clinical trial results evaluating the biologic for first-line non-squamous non-small cell lung cancer and metastatic breast cancer